BC Week In Review | May 12, 2008
Clinical News

ALS-357: Phase I/II start

Next quarter, Advanced Life Sciences will begin a dose-escalation Phase I/II trial in 12-16 patients. Advanced Life Sciences Inc. (NASDAQ:ADLS), Woodridge, Ill.   Product: ALS-357   Business: Cancer   Molecular target: NA   Description: Pentacyclic...
BC Week In Review | Sep 3, 2007
Clinical News

ALS-357 regulatory update

FDA granted Orphan Drug designation for ALS-357 to treat metastatic melanoma. ADLS plan to start a Phase I/II trial of the topical pentacyclic triterpenoid early next year. Advanced Life Sciences Inc. (ADLS), Woodridge, Ill.  ...
BC Week In Review | Sep 18, 2006
Clinical News

ALS-357: Phase I/II start

Next year, ADLS will start an open-label Phase I/II trial in 16 patients with unresectable metastatic melanoma. Advanced Life Sciences Inc. (ADLS), Woodridge, Ill.   Product: ALS-357   Business: Cancer   Molecular target: NA  ...
Items per page:
1 - 3 of 3